Please login to the form below

Not currently logged in
Email:
Password:

tumours

This page shows the latest tumours news and features for those working in and with pharma, biotech and healthcare.

Tecentriq combo fails in advanced triple negative breast cancer

Tecentriq combo fails in advanced triple negative breast cancer

The drug combination failed to achieve statistical significance on its primary endpoint of progression-free survival for the first-line treatment of people with advanced TNBC, whose tumours were ... Tecentriq has already been approved in combination with

Latest news

More from news
Approximately 9 fully matching, plus 1,128 partially matching documents found.

Latest Intelligence

  • Addressing the payer-regulator evidence gap in early-stage cancer Addressing the payer-regulator evidence gap in early-stage cancer

    Major pathologic response (MPR). 10% or less residual viable tumour cells detected in tumour samples removed during surgery or biopsy after treatment with radiation or chemotherapy. ... Circulating tumour DNA (ctDNA). Tumour-derived fragmented DNA in the

  • Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy

    It really drove us on and now we have the first drug to shrink the tumours. ... These tumours are slow-growing and vary in size, which leads to complications depending on the location of the tumour.

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    With longstanding competitors experiencing setbacks due to links with cardiovascular events and tumours, vadadustat’s success will be determined by its capacity to differentiate from other prolyl hydroxylase products, particularly from ... It is an

  • Staying ahead in the era of precision medicine Staying ahead in the era of precision medicine

    However, what was once homogeneous has now become heterogeneous. Different tumour subtypes have been identified, and exciting advances such as next-generation sequencing (NGS) of tumour DNA can more precisely define

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    Moreover, they think there is scope to extend the use of the drug to breast cancer and other solid tumours in patients who express lower levels of the HER2 biomarker than ... knocked back by an FDA advisory committee in 2019 but still in development –

More from intelligence
Approximately 0 fully matching, plus 87 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 19 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 35 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics